BioMérieux: Charles Cooper, Céline Roger-Dalbert, Mark Miller, François Lacoste
BioMérieux has appointed Charles Cooper as executive VP and chief medical officer, replacing Mark Miller effective Jan. 2, and Céline Roger-Dalbert as executive VP of research and development, replacing François Lacoste effective Mar. 1. Miller and Lacoste are both retiring.
Cooper previously served as CMO at Siemens Healthcare Diagnostics. He has also held positions at Becton Dickinson and the US Food and Drug Administration.
Roger-Dalbert previously held roles in R&D microbiology at BioMérieux and rejoined the company in 2022 serving as senior VP of research and development for clinical and regulatory affairs. In the interim, she served as Becton Dickinson's VP of R&D and program management in molecular, microbiology, and point-of-care diagnostics in Canada and the US.